The pandemic of coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an unprecedented challenge in terms of identifying effective prevention and treatment medications. Although some clinical research on traditional antiviral medicines have been undertaken around the world, the outcomes are still inconclusive. In general, the optimal treatment for COVID-19 patients is determined by a number of characteristics, including the disease's stage and symptoms. Administration of drugs among different patient populations may be difficult due to variances in individual genetics in drug metabolism as well as the diversity of immune responses to the coronavirus.
Title : Resveratrol derivatives a new tool for osteogenic induction in the treatment of peri implantitis
Barbara De Filippis, University “G. d’Annunzio, Italy
Title : Non-coding RNAs in the cardiovascular disorders linked to Chronic Kidney Disease
Laurent Metzinger, University of Picardie Jules Verne, France
Title : Drugs as an environmental problem chromatographic and computational studies of drugs partition between soil and water
Anna Weronika Sobanska, Medical University of Lodz, Poland
Title : miR-29b inhibition in triple negative cells target apoptosis and autophagy related mechanisms
Cornelia Braicu, Iuliu Haţieganu University of Medicine and Pharmacy, Romania
Title : Synthesis and in vitro study of antiproliferative heterocyclic scaffolds
Hitendra M Patel, Sardar Patel University, India
Title : Mucoadhesive microcapsule: A novel approach for controlling & sustained drug delivery!
Subas Chandra Dinda, Teerthanker Mahaveer University, India